Clinical Trial Update: Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations [Phase 3]

View source ↗

Summary

Open-label extension study update assessing safety and clinical utility of IPX203 for Parkinson's disease with motor fluctuations (Phase 3) has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• IPX203

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-06-06